Welcome to our dedicated page for EVERTEC news (Ticker: $EVTC), a resource for investors and traders seeking the latest updates and insights on EVERTEC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EVERTEC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EVERTEC's position in the market.
EVERTEC (NYSE: EVTC) has successfully repriced its $540 million Term Loan B (TLB), which is due in 2030. The new interest rate is set at SOFR + 325 basis points, down from SOFR + 350 basis points, reducing the cost by 25 basis points. This repricing does not affect the leverage of the company, and no other terms of the loan have been changed. Joaquin A. Castrillo-Salgado, the Executive Vice-President and CFO, highlighted the strong market demand for their debt, which has allowed EVERTEC to improve its capital structure and cash flow profile.
EVERTEC, Inc. (NYSE: EVTC) reported its first quarter 2024 results with revenue increasing by 28% to $205.3 million. GAAP Net Income decreased by 47% to $16.0 million. Adjusted EBITDA went up by 16% to $78.2 million. The company entered into an ASR agreement for $70 million. Overall, Evertec is pleased with its results and continues to expand in Latin America.